Taysha Gene Therapies Operating Income

Taysha Gene Therapies (TSHA) currently reports a operating income of $-150M as of June 2026. That compares with $-94M in the prior-year period — down 62.9% year over year. Use the charts on this page to explore Taysha Gene Therapies's operating income history and peer comparisons.

Taysha Gene Therapies's operating income decreased from $-94M to $-150M — a 62.9% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Taysha Gene Therapies reported $-150M in operating income as of June 2026. That compares with $-94M in the prior-year period — down 62.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-150M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Taysha Gene Therapies, and consider following TSHA for alerts when major investors trade the stock.

Taysha Gene Therapies is classified in the Healthcare sector. On operating income, it currently shows $-150M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TSHA with unrelated industries.